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LETTERS TO THE EDITORRegarding “Growth predictors and prognosis of small
abdominal aortic aneurysms”
We read with great interest the article by Schlösser et al1 who
concluded that lipid-lowering drug (statins) treatment and initial
abdominal aortic aneurysms (AAA) diameter appeared to be inde-
pendently associated with lower AAA growth rates. Statin therapy
reduces the progression of atherosclerosis and improves clinical
outcomes in cardiovascular disease, and there is evidence from a
number of studies to suggest that statins may influence aneurysm
growth rate presumably via pleiotropic effects.2 A prospective
randomized study would be justified on the basis of preliminary
findings, but it would hardly be feasible because the use of statins
is currently indicated in a growing number of patients with AAA
for the management of hypercholesterolemia as well as of coronary
and peripheral vascular disease.3 Therefore, we herein performed a
meta-analysis of currently available observational clinical studies of
statin therapy for reduction of AAA growth.
Our comprehensive search identified three observational clin-
ical studies (including the study by Schlösser et al)1,3,4 of statin
therapy vs control (no statin) enrolling patients with AAA. We
excluded the study by Sukhija et al,5 because no growth rates but
absolute growth was reported. In the retrospective study by
Mosorin et al,3 121 patients with AAA of at least 30 mm under-
going ultrasonographic scan surveillance for at least 1 year (serial
examinations at 3- to 12-month intervals) were included. In the
analysis by Schouten et al,4 150 patients under surveillance with a
follow-up for aneurysm growth of at least 12 months and a
minimum of 3 diameter evaluations were retrospectively included.
In total, our meta-analysis included data on 418 patients with AAA
assigned to statin therapy (n  156) or control (n  262). In the
studies by Schlösser et al1 and Schouten et al,4 adjusted mean
differences (MDs) of growth rates (mm/year) (ie, growth rates in
the statin group minus those in the control group) and 95%
confidence intervals (CIs) were reported. For the study by Mosorin
et al,3 data regarding crude growth rates in both the statin and
control groups were used to generate MDs and 95% CIs. Study-
specific estimates were combined using inverse variance-weighted
averages of logarithmic MDs in a random-effects model. Between-
study heterogeneity was analyzed by means of standard 2 tests.
Pooled analysis of the three studies demonstrated a statistically
significant 1.00 mm/year reduction in growth rate with statin
therapy relative to control (MD,1.00; 95% CI,1.54 to0.47;
P  .0002) (Fig). There was no between-study heterogeneity of
results (P  .71).
The results of our analysis suggest that statin therapy may
reduce AAA growth rates by 1.00 mm/year, which reinforcesFig. Mean differences of aneurysm growth rate and meta-
1638those of the study by Schlösser et al.1 The reduction in aneurysm
growth by statin therapy may prevent aneurysm repair or rupture.
If a randomized placebo-controlled trial is hardly possible,1 more
observational studies and a meta-analysis of them are needed to
confirm our results.
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Reply
We would like to thank Dr Takagi and his colleagues for their
thoughtful comments and additive meta-analysis on our article
about growth predictors and prognosis of small abdominal aortic
aneurysms (AAA). Their meta-analysis reinforces the conclusion
that statins are associated with lower AAA growth rates. The
relatively large number of patients included allowed for a more
precise estimate of the effect of statins on AAA growth rates.analysis. SE, Standard error; CI, confidence interval.
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College of Cardiology/American Heart Association (ACC/
AHA) guidelines, standard medical therapy of each patient with
peripheral atherosclerotic disease should include statins, if no
contraindication is present.1 Importantly, as shown by the
Reduction of Atherothrombosis for Continued Health
(REACH) registry, statins are underused in this patient popu-
lation.2 Besides the attenuation of AAA growth, statin treat-
ment improves long-term cardiac outcome of patients after
major vascular surgery, which is the predominant cause of late
mortality. In addition, statins also have a beneficial effect on the
early postoperative outcome. A meta-analysis by Hindler et al
showed that statin treatment was associated with a 59% reduc-
tion in overall short-term mortality after vascular surgery (1.7%
vs 6.1%; P  .0001),3 confirmed by the study of Feringa et al.4
In this study, statin users aged 65 years experienced a reduced
hospital mortality and long-term mortality after major non-
cardiac vascular surgery. In addition to survival benefits, statins
are also associated with a reduction in postoperative infections,5
improved recovery from acute kidney injury after major vascular
surgery,6 and improved preservation of renal function after
suprarenal aortic cross-clamping.7
We agree with the authors that a placebo-controlled ran-
domized trial cannot be justified anymore due to the continu-
ously growing evidence in literature of beneficial effects of
statins in patients with vascular diseases, including AAAs. Fu-
ture randomized trials may, however, improve treatment strat-
egies by comparing the effect of various statin therapies and
treatment targets on AAA growth rates and clinical outcomes in
patients with AAA.
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Regarding “Statins are independently associated with
reduced mortality in patients undergoing
infrainguinal bypass graft surgery for critical limb
ischemia”
Do statins save lives in patients undergoing infrainguinal by-
pass surgery for critical limb ischemia? Schanzer et al1 found that
the use of statin drugs was associated with a significant 1-year
survival benefit in patients undergoing surgical bypass grafting for
critical limb ischemia. However, the authors did not appear to
consider baseline cholesterol, as hypercholesterolemia is strikingly
related to statin use.1
It is well known that among hospitalized disabled older
adults, elevated levels of cholesterol are associated with an
increased rate of recovery from disability in basic activities of
daily living.2 On the other hand, in surgical patients, hypocho-
lesterolemia is a strong predictor of in-hospital death, nosoco-
mial infections, and length of hospital stay.3 Furthermore, in
patients undergoing general surgery, a low total cholesterol
level has been shown to be strongly associated with death after
2 years after discharge from the hospital.4
Curiously, a subgroup analysis of the Heart Protection Study
focusing on patients with peripheral artery disease5 failed to con-
sider mortality data by combining deaths with aneurysm repairs.
They found a small increase among those randomized to simvasta-
tin for this combined end point.5 Therefore, it is highly plausible
that in the study by Schanzer et al,1 statin use selected the healthy
statin user or unselected the unhealthy low-cholesterol patient.
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